Obesity

Latest News

Semaglutide Supports Long-Term Weight Loss, Reduces CV Risk Across BMI Subgroups
Semaglutide Supports Long-Term Weight Loss, Reduces CV Risk Across BMI Subgroups

May 15th 2024

Analyses of the SELECT trial found mean weight loss of 10.2% sustained for 4 years and comparable CV benefit with weight loss greater or less than 5%, or even weight gain.

Poor Cardiovascular-Kidney-Metabolic Health “Widespread” among US Adults, According to New Study
Poor Cardiovascular-Kidney-Metabolic Health “Widespread” among US Adults, According to New Study

May 8th 2024

American Liver Foundation Announces First Federally-Funded Research on MASLD / image credit American Liver Foundation  Lorraine Stiehl
American Liver Foundation Announces First Federally-Funded Research on MASLD

April 26th 2024

Adults with Obesity Who Receive Semaglutide as First Weight Loss Medication Lose More Weight / image credit ©brovarky/stock.adobe.com
Adults with Obesity Who Receive Semaglutide as First Weight Loss Medication Lose More Weight

April 25th 2024

© 2024 MJH Life Sciences

All rights reserved.